Minerva Neurosciences (NASDAQ:NERV) Now Covered by StockNews.com
StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Free Report) in a research report report published on Friday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Separately, HC Wainwright restated a “neutral” rating and set a $5.00 target price on shares of Minerva Neurosciences in a report on Wednesday, November […]
StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Free Report) in a research report report published on Friday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Separately, HC Wainwright restated a “neutral” rating and set a $5.00 target price on shares of Minerva Neurosciences in a report on Wednesday, November […]
